Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 Nov;60(Suppl 3):iii41–iii42. doi: 10.1136/ard.60.90003.iii41

Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines

P Greenberg
PMCID: PMC1766670  PMID: 11890651

Full Text

The Full Text of this article is available as a PDF (63.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali A., Mundle S. D., Ragasa D., Reza S., Shetty V., Mativi B. Y., Cartlidge J. D., Azharuddin M., Qawi H., Dar S. Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res. 1999 Aug;8(4):343–356. doi: 10.1089/152581699320108. [DOI] [PubMed] [Google Scholar]
  2. Bouscary D., De Vos J., Guesnu M., Jondeau K., Viguier F., Melle J., Picard F., Dreyfus F., Fontenay-Roupie M. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997 Jun;11(6):839–845. doi: 10.1038/sj.leu.2400654. [DOI] [PubMed] [Google Scholar]
  3. Deeg H. J., Beckham C., Loken M. R., Bryant E., Lesnikova M., Shulman H. M., Gooley T. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma. 2000 Apr;37(3-4):405–414. doi: 10.3109/10428190009089441. [DOI] [PubMed] [Google Scholar]
  4. Gersuk G. M., Beckham C., Loken M. R., Kiener P., Anderson J. E., Farrand A., Troutt A. B., Ledbetter J. A., Deeg H. J. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998 Oct;103(1):176–188. doi: 10.1046/j.1365-2141.1998.00933.x. [DOI] [PubMed] [Google Scholar]
  5. Gersuk G. M., Lee J. W., Beckham C. A., Anderson J., Deeg H. J. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood. 1996 Aug 1;88(3):1122–1123. [PubMed] [Google Scholar]
  6. Greenberg P. L. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res. 1998 Dec;22(12):1123–1136. doi: 10.1016/s0145-2126(98)00112-x. [DOI] [PubMed] [Google Scholar]
  7. Hellström-Lindberg E., Schmidt-Mende J., Forsblom A. M., Christensson B., Fadeel B., Zhivotovsky B. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol. 2001 Mar;112(3):714–726. doi: 10.1046/j.1365-2141.2001.02581.x. [DOI] [PubMed] [Google Scholar]
  8. Parker J. E., Mufti G. J., Rasool F., Mijovic A., Devereux S., Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000 Dec 1;96(12):3932–3938. [PubMed] [Google Scholar]
  9. Rajapaksa R., Ginzton N., Rott L. S., Greenberg P. L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood. 1996 Dec 1;88(11):4275–4287. [PubMed] [Google Scholar]
  10. Shetty V., Mundle S., Alvi S., Showel M., Broady-Robinson L., Dar S., Borok R., Showel J., Gregory S., Rifkin S. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996 Nov-Dec;20(11-12):891–900. doi: 10.1016/s0145-2126(96)00008-2. [DOI] [PubMed] [Google Scholar]
  11. Shimazaki K., Ohshima K., Suzumiya J., Kawasaki C., Kikuchi M. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br J Haematol. 2000 Sep;110(3):584–590. doi: 10.1046/j.1365-2141.2000.02228.x. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES